DrugPatentWatch Database Preview

Details for Patent: 8,754,109

« Back to Dashboard

Which drugs does patent 8,754,109 protect, and when does it expire?

Patent 8,754,109 protects ESBRIET and is included in two NDAs.

This patent has thirty-seven patent family members in twenty-seven countries.

Summary for Patent: 8,754,109

Title:	Pirfenidone therapy and inducers of cytochrome P450
Abstract:	The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
Inventor(s):	Bradford; Williamson Z. (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee:	Intermune, Inc. (Brisbane, CA)
Application Number:	13/513,472
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,754,109
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 8,754,109
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,754,109

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genentech Inc	ESBRIET	pirfenidone	CAPSULE;ORAL	022535-001	Oct 15, 2014		RX	Yes	Yes						METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-001	Jan 11, 2017		RX	Yes	No						ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-002	Jan 11, 2017		DISCN	Yes	No						ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
Genentech Inc	ESBRIET	pirfenidone	TABLET;ORAL	208780-003	Jan 11, 2017		RX	Yes	Yes						ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY

Foreign Priority and PCT Information for Patent: 8,754,109

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	10250378	Mar 3, 2010
Canada	2710014	Oct 8, 2010

PCT Information
PCT Filed	December 03, 2010	PCT Application Number:	PCT/US2010/058936
PCT Publication Date:	June 09, 2011	PCT Publication Number:	WO2011/069089

International Family Members for US Patent 8,754,109

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	523197
Australia	2010212488
Canada	2710014
Cyprus	1112075